Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Emerging Treatments In Acute Myeloid Leukemia (AML)

This program will discuss several investigational agents for the treatment of AML. Acute myeloid leukemia (AML) is a relatively uncommon but difficult-to-treat hematologic malignancy. AML is defined by the World Health...
CME credit is no longer available for this conference.

Course Authors

Mary-Elizabeth M. Percival, M.D., M.S. and Roland B. Walter, M.D., Ph.D., M.S.

Dr. Percival is Assistant Professor of Medicine, University of Washington School of Medicine, and Assistant Member, Fred Hutchinson Cancer Research Center, and Dr. Walter is Associate Professor of Medicine, University of Washington School of Medicine, and Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Within the past 12 months, Dr. Percival has received clinical trial support from FLXBio and Dr. Walter has been a consultant to Agios Therapeutics, Amphivena Therapeutics, AstraZeneca, Covagen AG, Emergent Biosolutions, Janssen R&D, Pfizer and Seattle Genetics; received clinical trial/lab support from AbbVie, ADC Therapeutics, Amgen, Amphivena Therapeutics, Arog Pharmaceuticals, Celator, Covagen, Pharmcyclics, Seattle Genetics and Stemline Therapeutics; and has ownership interest in Amphivena Therapeutics.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Describe standard treatments for newly diagnosed AML for adults of all ages, including induction chemotherapy and allogeneic hematopoietic cell transplantation (HCT);

  • List the areas in which new treatments are needed;

  • Appreciate the importance of targeted therapies, such as small molecule inhibitors or antibodies, as an adjunct to standard AML treatments.



The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.


Please click below to accept the terms of this CME activity

Courses You Might Like


Estimated Time: 6 Hours

Unexplained Bleeding in Hospitalized Patients

This presentation may include discussion of commercial products and services. A 65-year-old man is hospitalized for cerebellar infarction. At admission, he was drowsy, without clinical evidence of bleeding. He was administered aspirin, clopidogrel and valproate for cerebellar infarction; a statin for hyperlipidemia; and clindamycin and teicoplanin for aspiration pneumonia. Following intubation, a tracheostomy was performed. Bleeding history: No previous familial medical history of bleeding or coagulopathy; no clinical symptoms or signs of malignancy, antiphospholipid syndrome or collagen vascular disease. Initial laboratory
Authors: Meera B. Chitlur, M.D.
Estimated Time: 1 Hour

Lung Cancer Chemoprevention

Lung cancer is now the leading cause of cancer death in both men and women in the United States, as well as the leading cause of cancer death worldwide. The 5-year U.S. survival rate for lung cancer is a discouraging 16%, and while there has been an interval improvement in survival, the survival advances realized in other common malignancies have not translated to lung cancer. One reason for the discouraging survival statistics is that the majority of patients present
Authors: Robert L. Keith, M.D.
Estimated Time: 1 Hour

Molecularly Targeted Therapy for Malignant Brain Tumors

Gliomas are the most frequently occurring malignant primary brain tumors and include astrocytomas, oligodendrogliomas and ependymomas. Combined, these histologies account for approximately 40% of all primary brain tumors and over 80% of all malignant CNS tumors. Typically, high−grade gliomas (Grades III and IV) are referred to as “malignant” glioma. As glioblastoma (GBM), the only grade IV glioma, accounts for approximately 50% of gliomas, a majority of glioma research has focused on this tumor type (see Figure
Authors: Nicole A. Shonka, M.D., and Mark R. Gilbert, M.D.
Estimated Time: 1 Hour

Anti-EGFR Therapy: Incidence, Pathology and Management of Associated Side Effects

The severity of EGFR-related dermatological adverse events is graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (Table 1). EGFR is expressed widely in human tissue including the epidermis, sweat gland apparatus and the hair follicle epithelium. , , The cutaneous reactions to EGFR inhibitors include follicular eruptions, generalized xerosis, pruritis, hyperpigmentation, panniculitis, paronychia, alopecia, trichomegaly, fine brittle hair, ocular irritation and vaginal dryness (Table 2). Current data suggest that skin eruption in patients taking
Authors: Sunil Babu, M.D., Michael Liu, M.D., and Robert G. Lerner, M.D.
Estimated Time: 1 Hour